pan-vegf capture antibody Search Results


pan vegf capture antibody  (R&D Systems)
93
R&D Systems pan vegf capture antibody
Pan Vegf Capture Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan vegf capture antibody/product/R&D Systems
Average 93 stars, based on 1 article reviews
pan vegf capture antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
human vegf165 antibody  (Bio-Techne corporation)
94
Bio-Techne corporation human vegf165 antibody
Human Vegf165 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human vegf165 antibody/product/Bio-Techne corporation
Average 94 stars, based on 1 article reviews
human vegf165 antibody - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
pan-vegf capture antibody  (R&D Systems)
90
R&D Systems pan-vegf capture antibody
Effect of SRPK1 inhibitors on <t>VEGF</t> and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF <t>by</t> <t>ELISA.</t> Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).
Pan Vegf Capture Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan-vegf capture antibody/product/R&D Systems
Average 90 stars, based on 1 article reviews
pan-vegf capture antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pan vegf antibody  (R&D Systems)
92
R&D Systems pan vegf antibody
Effect of SRPK1 inhibitors on <t>VEGF</t> and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF <t>by</t> <t>ELISA.</t> Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).
Pan Vegf Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan vegf antibody/product/R&D Systems
Average 92 stars, based on 1 article reviews
pan vegf antibody - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
pan vegf mouse capture antibody  (R&D Systems)
92
R&D Systems pan vegf mouse capture antibody
Effect of SRPK1 inhibitors on <t>VEGF</t> and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF <t>by</t> <t>ELISA.</t> Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).
Pan Vegf Mouse Capture Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan vegf mouse capture antibody/product/R&D Systems
Average 92 stars, based on 1 article reviews
pan vegf mouse capture antibody - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
human vegf 165b duoset elisa  (Bio-Techne corporation)
94
Bio-Techne corporation human vegf 165b duoset elisa
Effect of SRPK1 inhibitors on <t>VEGF</t> and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF <t>by</t> <t>ELISA.</t> Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).
Human Vegf 165b Duoset Elisa, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human vegf 165b duoset elisa/product/Bio-Techne corporation
Average 94 stars, based on 1 article reviews
human vegf 165b duoset elisa - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
human/primate vegf antibody  (Bio-Techne corporation)
94
Bio-Techne corporation human/primate vegf antibody
Effect of SRPK1 inhibitors on <t>VEGF</t> and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF <t>by</t> <t>ELISA.</t> Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).
Human/Primate Vegf Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human/primate vegf antibody/product/Bio-Techne corporation
Average 94 stars, based on 1 article reviews
human/primate vegf antibody - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
96-well sterile plates  (Greiner Bio)
90
Greiner Bio 96-well sterile plates
Effect of SRPK1 inhibitors on <t>VEGF</t> and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF <t>by</t> <t>ELISA.</t> Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).
96 Well Sterile Plates, supplied by Greiner Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/96-well sterile plates/product/Greiner Bio
Average 90 stars, based on 1 article reviews
96-well sterile plates - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
quantitative polymerase chain reaction (qpcr)  (PrimerDesign Inc)
90
PrimerDesign Inc quantitative polymerase chain reaction (qpcr)
Effect of SRPK1 inhibitors on <t>VEGF</t> and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF <t>by</t> <t>ELISA.</t> Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).
Quantitative Polymerase Chain Reaction (Qpcr), supplied by PrimerDesign Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/quantitative polymerase chain reaction (qpcr)/product/PrimerDesign Inc
Average 90 stars, based on 1 article reviews
quantitative polymerase chain reaction (qpcr) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pbs  (Greiner Bio)
96
Greiner Bio pbs
Effect of SRPK1 inhibitors on <t>VEGF</t> and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF <t>by</t> <t>ELISA.</t> Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).
Pbs, supplied by Greiner Bio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pbs/product/Greiner Bio
Average 96 stars, based on 1 article reviews
pbs - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
human vegf duoset elisa  (Bio-Techne corporation)
97
Bio-Techne corporation human vegf duoset elisa
Effect of SRPK1 inhibitors on <t>VEGF</t> and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF <t>by</t> <t>ELISA.</t> Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).
Human Vegf Duoset Elisa, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human vegf duoset elisa/product/Bio-Techne corporation
Average 97 stars, based on 1 article reviews
human vegf duoset elisa - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

Image Search Results


Effect of SRPK1 inhibitors on VEGF and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF by ELISA. Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).

Journal: Investigative Ophthalmology & Visual Science

Article Title: Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD

doi: 10.1167/iovs.13-12422

Figure Lengend Snippet: Effect of SRPK1 inhibitors on VEGF and SR protein phosphorylation. (A) ARPE-19 cells were treated with 10 μM SRPIN340, MVRL09, SPHINX, or left untreated, and subsequently either treated or not with EGF. Extracted protein was run on Western blots for phospho-SR proteins. (A) Bands were observed at molecular weights corresponding to SRSF1/2, SRSF4, and SRSF6, densitometry analysis was undertaken on SRSF1/2. SRPK inhibition significantly reduced the endogenous phosphorylation of SRSF1/2, moreover pre-incubation of cells with either SRPIN340 or SPHINX significantly blocked an EGF-induced increase in SR protein phosphorylation. (B) Serum-starved primary RPE cells and ARPE-19 cells were treated with inhibitors at 5 μM. Twenty-four hours later, RNA was extracted and cDNA was made. PCR was performed with primers spanning VEGF exon 7b and 8b. Treatment with the inhibitors reduced the expression of VEGF165 relative to GAPDH control either in primary RPE cells (SRPIN340) or both cell lines (SPHINX and MVRL09). Water (W) and sample without RT were used as negative controls. (C) Forty-eight hours after treatment, protein was extracted and assayed for total VEGF by ELISA. Protein was assessed using a VEGFxxxb-specific ELISA and the ratio of VEGFxxxb over total VEGF calculated. The ratio increased in ARPE-19 during treatment with SPHINX and SRPIN340, and in primary RPE during treatment with SPHINX and MVRL09. Total VEGF expression relative to total protein was also calculated. In primary RPE, VEGF expression was reduced following SRPIN340 and MVRL09 treatment, in ARPE-19, VEGF expression was increased following SPHINX and MVRL09 treatment (One-way ANOVA, Bonferroni post hoc. *P < 0.05, **P < 0.01).

Article Snippet: One microgram per milliliter pan-VEGF capture antibody (Duoset VEGF ELISA DY-293; R&D Systems, Abingdon, UK) was incubated overnight at room temperature.

Techniques: Western Blot, Inhibition, Incubation, Expressing, Enzyme-linked Immunosorbent Assay